{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:48:43Z","timestamp":1789886923143,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["1308085MH169"],"award-info":[{"award-number":["1308085MH169"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.arcmed.2016.05.006","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T00:25:36Z","timestamp":1464654336000},"page":"223-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Xiao-lei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2016.05.006_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0092-8674(00)81110-1","article-title":"Genetic analysis of autoimmune disease","volume":"85","author":"Vyse","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.arcmed.2016.05.006_bib2","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMra1100030","article-title":"Genomics and the multifactorial nature of human autoimmune disease","volume":"365","author":"Cho","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2016.05.006_bib3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2011.10.022","article-title":"Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?","volume":"11","author":"Costenbader","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.arcmed.2016.05.006_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.153.4.977","article-title":"Hamster female protein. A new pentraxin structurally and functionally similar to C-reactive protein and amyloid P component","volume":"153","author":"Coe","year":"1981","journal-title":"J Exp Med"},{"key":"10.1016\/j.arcmed.2016.05.006_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semarthrit.2008.03.006","article-title":"The long pentraxin 3 and its role in autoimmunity","volume":"39","author":"Ortega-Hernandez","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.arcmed.2016.05.006_bib6","doi-asserted-by":"crossref","first-page":"8303","DOI":"10.4049\/jimmunol.175.12.8303","article-title":"TNF alpha induced long pentraxin PTX3 expression in human lung epithelial cells via JNK","volume":"175","author":"Han","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13223-015-0104-y","article-title":"TNF up-regulates Pentraxin3 expression in human airway smooth muscle cells via JNK and ERK1\/2 MAPK pathways","volume":"11","author":"Zhang","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1189\/jlb.0905493","article-title":"Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma","volume":"79","author":"Doni","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib9","doi-asserted-by":"crossref","first-page":"e34965","DOI":"10.1371\/journal.pone.0034965","article-title":"Pentraxin 3 (PTX3) expression in allergic asthmatic airways: role in airway smooth muscle migration and chemokine production","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2016.05.006_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08916934.2011.611549","article-title":"Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications","volume":"45","author":"Cie\u015blik","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.arcmed.2016.05.006_bib11","doi-asserted-by":"crossref","first-page":"e0119709","DOI":"10.1371\/journal.pone.0119709","article-title":"The long pentraxin PTX3 promotes fibrocyte differentiation","volume":"10","author":"Pilling","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2016.05.006_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/acr.20094","article-title":"Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease","volume":"62","author":"Hollan","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.arcmed.2016.05.006_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12016-015-8476-9","article-title":"PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis","volume":"49","author":"Bassi","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/08916934.2014.983264","article-title":"Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus","volume":"48","author":"Cie\u015blik","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.arcmed.2016.05.006_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/14397595.2013.852837","article-title":"Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus","volume":"24","author":"Shimada","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib16","first-page":"354014","article-title":"Pentraxin 3 Plasma Levels and Disease Activity in Systemic Lupus Erythematosus","volume":"2015","author":"Assandri","year":"2015","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.arcmed.2016.05.006_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jbspin.2014.09.003","article-title":"Pentraxin-3 levels in systemic lupus erythematosus: association with cumulative damage but not with disease activity","volume":"82","author":"Skare","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.arcmed.2016.05.006_bib18","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1002\/1529-0131(200112)44:12<2841::AID-ART472>3.0.CO;2-6","article-title":"PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation","volume":"44","author":"Fazzini","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arcmed.2016.05.006_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3899\/jrheum.130803","article-title":"Blood monocyte heterogeneity and markers of endothelial activation in ankylosing spondylitis","volume":"41","author":"Surdacki","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib20","first-page":"137","article-title":"Levels of pentraxin 3 and relationship with disease activity in patients with ankylosing spondylitis","volume":"39","author":"Deniz","year":"2014","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.arcmed.2016.05.006_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s13075-014-0413-4","article-title":"Calprotectin (S100A8\/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis","volume":"16","author":"Turina","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.arcmed.2016.05.006_bib22","doi-asserted-by":"crossref","first-page":"681635","DOI":"10.1155\/2014\/681635","article-title":"Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration","volume":"2014","author":"Klimek","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.arcmed.2016.05.006_bib23","doi-asserted-by":"crossref","first-page":"e55346","DOI":"10.1371\/journal.pone.0055346","article-title":"Blood monocyte chemotactic protein-1 (MCP-1) and adapted disease activity Score28-MCP-1: favorable indicators for rheumatoid arthritis activity","volume":"8","author":"Liou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2016.05.006_bib24","first-page":"87","article-title":"Serum pentraxin 3 and interleukin-6 are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis","volume":"17","author":"Mabrouk","year":"2010","journal-title":"Egypt J Immunol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3899\/jrheum.080343","article-title":"Increased serum pentraxin 3 in patients with systemic sclerosis","volume":"36","author":"Iwata","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.38953","article-title":"Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis","volume":"67","author":"Shirai","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib27","doi-asserted-by":"crossref","first-page":"e0130166","DOI":"10.1371\/journal.pone.0130166","article-title":"Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide","volume":"10","author":"Borghini","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2016.05.006_bib28","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/1352458512457845","article-title":"Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica","volume":"19","author":"Wang","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.arcmed.2016.05.006_bib29","first-page":"603","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of case-control studies in meta-analyses","volume":"25","author":"Wells","year":"2011","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib30","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/eurheartj\/ehn333","article-title":"Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials","volume":"29","author":"Whitlock","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arcmed.2016.05.006_bib31","doi-asserted-by":"crossref","first-page":"1539e1558","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.arcmed.2016.05.006_bib32","first-page":"173","article-title":"Clearance of apoptotic cells in human SLE","volume":"9","author":"Gaipl","year":"2006","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.arcmed.2016.05.006_bib33","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1182\/blood.V96.13.4300","article-title":"The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells","volume":"96","author":"Rovere","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2016.05.006_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/ken507","article-title":"Detection of anti-PTX3 autoantibodies in systemic lupus erythematosus","volume":"48","author":"Augusto","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arcmed.2016.05.006_bib35","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/ard.2009.117804","article-title":"IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus","volume":"69","author":"Bassi","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arcmed.2016.05.006_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21767\/2172-0479.100005","article-title":"Pentraxin 3 in systemic lupus erithematosus: questions to be Resolved","volume":"6","author":"Assandri","year":"2015","journal-title":"Transl Biomed"},{"key":"10.1016\/j.arcmed.2016.05.006_bib37","first-page":"773","article-title":"Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus","volume":"27","author":"Kim","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 33","key":"10.1016\/j.arcmed.2016.05.006_bib38","first-page":"S66","article-title":"Scleroderma fibroblasts constitutively express the long pentraxin PTX3","volume":"22","author":"Luchetti","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","article-title":"Vasculopathy in scleroderma","volume":"37","author":"Asano","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib40","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/art.27522","article-title":"Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12","volume":"62","author":"Margheri","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arcmed.2016.05.006_bib41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1365-2249.2000.01110.x","article-title":"Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA)","volume":"119","author":"Luchetti","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib42","doi-asserted-by":"crossref","first-page":"32817","DOI":"10.1074\/jbc.272.52.32817","article-title":"Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component","volume":"272","author":"Bottazzi","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arcmed.2016.05.006_bib43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.rdc.2005.01.006","article-title":"Inflammation and accelerated atherosclerosis: basic mechanisms","volume":"31","author":"Doria","year":"2005","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.arcmed.2016.05.006_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2007.02.004","article-title":"The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia","volume":"28","author":"Hahn","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.arcmed.2016.05.006_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosis.2004.03.020","article-title":"Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells","volume":"175","author":"Klouche","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arcmed.2016.05.006_bib46","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.39033","article-title":"Assessment of elevated pentraxin 3 levels in systemic sclerosis: comment on the article by Shirai et\u00a0al","volume":"67","author":"Agilli","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jneuroim.2014.03.014","article-title":"Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis","volume":"271","author":"Rosjo","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.arcmed.2016.05.006_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MCA.0b013e328352ffec","article-title":"Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin","volume":"23","author":"Iwata","year":"2012","journal-title":"Coron Artery Dis"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440916300200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440916300200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:44:17Z","timestamp":1759261457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440916300200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0188440916300200"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2016.05.006","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2016.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}